Updated on 30 December 2014
BioTime is a pluripotent stem cell technology firm, a powerful platform with the potential for new therapies
Singapore: Stem cell therapy company, BioTime, has appointed Mr Adi Mohanty, ex-Shire executive, as chief operating officer and would be reponsible to build BioTime's business through the development of its subsidiaries and through the further development and commercialization of BioTime's HyStem-based products.
"The addition of Adi to our senior management team is another execution milestone for BioTime as we broaden our capabilities to address market opportunities and build shareholder value," said Dr Michael D West, CEO, BioTime.
"Adi is a highly experienced biopharmaceutical executive. He joins our company at a time when two of our subsidiaries have been cleared for clinical trials of their therapeutic products and as we develop commercialization strategies for cancer diagnostics and Renevia, he added.
"Adi's extensive background in managing multiple, successful clinical and commercial-stage products is very relevant to BioTime's growth," continued Dr West. "He is a proven business leader, having served in such roles at both Shire plc and at Transkaryotic Therapies. His experience and insight, combined with those of the biopharmaceutical veterans from Questcor Pharmaceuticals and Shire who have recently joined our Board of Directors, provide us a team with a tremendous track record for generating shareholder value. Our objective is to fully utilize Adi's knowledge and experience, as well as that of our Board members, as we move BioTime forward during 2015 and beyond."